We hypothesize that ID is an important factor in the limitation of exercise capacity in HFpEF. Systemic low-grade inflammation does not only lead to microvascular dysfunction but also to iron deficiency. Iron deficiency has a direct effect on the…
ID
Bron
Verkorte titel
Aandoening
Diabetes, obesity and hypertension, all highly present comorbidities in HFpEF, seem to drive this disease by inducing low-grade systemic inflammation which in turn induces microvascular dysfunction and activates a cascade of events. Several studies have demonstrated that HFpEF is a systemic disease that affects not only cardiac, but also peripheral muscle energy metabolism. Iron deficiency (ID) could be an important contributor in this pathophysiological process.
Iron deficiency is present in 50% of chronic HF patients. Although HFpEF was not excluded from these cohort studies, it mainly included HF with reduced ejection fraction (HFrEF).
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
- Is skeletal muscle metabolism impaired in HFpEF patients with iron deficiency, measured using CMR spectroscopy?
Achtergrond van het onderzoek
Diabetes, obesity and hypertension, all highly present comorbidities in HFpEF, seem to drive this disease by inducing low-grade systemic inflammation which in turn induces microvascular dysfunction and activates a cascade of events. Several studies have demonstrated that HFpEF is a systemic disease that affects not only cardiac, but also peripheral muscle energy metabolism. Iron deficiency (ID) could be an important contributor in this pathophysiological process.
Iron deficiency is present in 50% of chronic HF patients. Although HFpEF was not excluded from these cohort studies, it mainly included HF with reduced ejection fraction (HFrEF).
We hypothesize that ID is an important factor in the limitation of exercise capacity in HFpEF. Systemic low-grade inflammation does not only lead to microvascular dysfunction but also to iron deficiency. Iron deficiency has a direct effect on the muscle. Not only on the cardiac muscle but also the skeletal muscle is affected, impairing muscle contraction strength but also energy metabolism. The primary focus of this study will be delivering proof that the alterations in the muscle are more severe in HFpEF patients with ID compared to without ID.
Doel van het onderzoek
We hypothesize that ID is an important factor in the limitation of exercise capacity in HFpEF. Systemic low-grade inflammation does not only lead to microvascular dysfunction but also to iron deficiency. Iron deficiency has a direct effect on the muscle. Not only on the cardiac muscle but also the skeletal muscle is affected, impairing muscle contraction strength but also energy metabolism. The primary focus of this study will be delivering proof that the alterations in the muscle are more severe in HFpEF patients with ID compared to without ID.
Onderzoeksopzet
Not aplicable
Onderzoeksproduct en/of interventie
o Measurement of PCR recovery time using MR spectroscopy
- Microvascular function
o Glycocalyx thickness (um)
o Heat induced hyperaemic response (% skin hyperaemic response)
- Exercise tolerance
o 6 minute walk test distance (m)
o maximum exercise capacity (METs on exercise test)
Algemeen / deelnemers
Arantxa Barandiaran
Maastricht University Medical Centre, Department of Cardiology
Maastricht 6202 AZ
The Netherlands
+31(0)43-3871148
arantxa.barandiaranaizpurua@mumc.nl
Wetenschappers
Arantxa Barandiaran
Maastricht University Medical Centre, Department of Cardiology
Maastricht 6202 AZ
The Netherlands
+31(0)43-3871148
arantxa.barandiaranaizpurua@mumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
• HFpEF: according to the ESC guidelines
(1) Signs and/or symptoms of heart failure,
(2) LVEF ≥ 50%,
(3) Elevated levels of natriuretic peptide (NT-proBNP > 125 pg/ml
~ 15 pmol/L)
(4) one of the following additional criteria
a) Relevant structural heart disease; LV hypertrophy, (LVmass index > 95 g/m2 in women, or >115 g/m2 in men) and/or LA enlargement (LA volume index >34 l/m2)
b) Diastolic dysfunction (E/e’ ≥ 13, mean e’ septal and lateral wall < 9 cm/s)
• Iron deficiency: serum ferritin < 100 µg/L or serum ferritin between 100-299 µg/L in combination with a transferrin saturation < 20%.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Reproductive age women
- Any iron supplement (oral, iv) during the last 6 months prior to inclusion
- Any chemotherapy in last year
- Significant peripheral artery disease
- Contraindication for CMR
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
Register | ID |
---|---|
NTR-new | NL7059 |
NTR-old | NTR7297 |
CCMO | NL65600.068.18 |
OMON | NL-OMON55673 |